Narrative review / 2017
Pomegranate products are safe but failed to significantly prolong PSA doubling time in a phase III trial of prostate cancer patients with biochemical recurrence.
This review examined clinical trials of pomegranate juice, extract, and supplements across various prostate cancer patient populations. In biochemical recurrence (BCR) patients, early phase II trials showed significant lengthening of PSA doubling time (PSADT), but a placebo-controlled phase III trial found no significant prolongation overall, although a preplanned subset with the MnSOD AA genotype showed greater PSADT lengthening. Phase II trials of 100% pomegranate products in neoadjuvant patients and metastatic castration-resistant prostate cancer were negative. A trial of a polyphenol-rich multicomponent food supplement containing 31.25% pomegranate extract significantly slowed PSA increase compared with placebo in men on active surveillance or experiencing BCR.
- Study type
- Narrative review of clinical trials
- Who was studied
- Patients with prostate cancer across multiple clinical trials
- What was measured
- PSA doubling time, tissue oxidation markers, and other clinical outcomes
THE PAPER
A review of pomegranate in prostate cancer.
Paller CJ, Pantuck A, Carducci MA. Prostate Cancer Prostatic Dis, 2017.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.